Determination of Blood Tumor Cells
Status
Conditions
Details and patient eligibility
About
Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .
Full description
Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood.
Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)
Exclusion criteria
Inability to understand the language of the center (German)
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal